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Abstract
BACKGROUND—Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are common and 
contribute to morbidity and mortality. Duration of IV antibiotic therapy to treat PEx varies widely 
in the US, and there are few data to guide treatment decisions.
METHODS—We combined a survey of CF stakeholders with retrospective analyses of a recent 
observational study of CF PEx to design a multicenter, randomized, prospective study comparing 
the efficacy and safety of different durations of IV antibiotics for PEx to meet the needs of people 
with CF and their caregivers.
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RESULTS—IV antibiotic duration was cited as the most important PEx research question by 
responding CF physicians and top concern among surveyed CF patients/caregivers. During PEx, 
forced expiratory volume in 1 second (FEV1 %predicted) and symptom responses at 7–10 days of 
IV antibiotics identified two distinct groups: early robust responders (ERR) who subsequently 
experienced greater FEV 1 improvements compared to non-ERR (NERR). In addition to greater 
FEV1 and symptom responses, only 14% of ERR patients were treated with IV antibiotics for >15 
days, compared with 45% of NERR patients.
CONCLUSIONS—A divergent trial design that evaluates subjects’ interim improvement in 
FEV 1 and symptoms to tailor randomization to IV treatment duration (10 vs. 14 days for ERR, 14 
vs. 21 days for NERR) may alleviate physician and patient concerns about excess or inadequate 
treatment. Such a study has the potential to provide evidence necessary to standardize IV antibiotic 
duration in CF PEx care –a first step to conducting PEx research of other treatment features.
Keywords
cystic fibrosis; FEV1; symptoms; pulmonary exacerbation
INTRODUCTION
Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are a major cause of morbidity linked 
to disease progression [1][2] and diminished survival [3][4]. They are common and recurring 
[5], typically treated with antibiotics and increased airway clearance [6]. A systematic 
review of the literature found scant evidence upon which to base treatment recommendations 
[7]. Analysis of the CF Foundation (CFF) Patient Registry (CFFPR) demonstrates wide 
variation in treatment parameters [5] making it difficult to determine optimal practice [6]. 
This is particularly important as analysis of the CFFPR suggested a lack of recovery of lung 
function to previous baseline [8]. There are many reports of risk factors for PEx outcomes 
but nearly all are based on either observational data subject to indication bias [9][10][11]
[12], or small single center randomized studies with inconclusive findings [13][14][15][16]
[17].
Identification of best PEx treatment practices is hindered by multiple logistic barriers, 
including variability of presenting signs and symptoms [18], diverse physician and patient 
objectives for treatment [19], and the range of treatment combinations currently utilized 
[12]. Ideally, PEx treatment practices could be optimized by conducting a series of 
randomized controlled studies comparing differences in a single parameter (e.g., treatment 
durations, home vs. hospital treatment). It has been suggested that studying differences in 
treatment duration may be the ‘most logical’ parameter for initial PEx treatment studies 
[20].
The Standardized Treatment of Pulmonary Exacerbations (STOP) study was an 
observational pilot study of individuals with CF who were admitted to the hospital for 
intravenous (IV) antibiotics for treatment of a PEx. STOP gathered PEx presentation 
characteristics, physician goals and treatment choices, physician willingness to enroll 
patients in hypothetical trials, and clinical response[18][19][21], with the ultimate objective 
of leveraging results to design future controlled interventional trials standardizing aspects of 
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CF PEx treatment. While STOP identified a general willingness of CF physicians 
participating in the study to participate in standardized PEx studies, it was necessary to get 
broader input from other CF clinicians, patients and families to understand prioritization of 
PEx treatment questions and clinical response measures, and specific concerns regarding the 
design of randomized prospective studies in PEx.
We describe the survey results and report retrospective analyses of the STOP study to 
rationalize and design a multicenter, randomized, prospective study comparing the clinical 
efficacy and safety of different durations of IV antibiotic treatment.
MATERIALS AND METHODS
Stakeholder Surveys
Two surveys were developed to gauge PEx experiences, perceptions, and research 
importance among 1) CF patients/caregivers, and 2) CF physicians/providers [Appendices 
B,C in the data supplement]. The patient/caregiver questionnaire was distributed via email to 
150 patients and caregivers in the CFF-organized Adult and Patient Family Advisory group 
(AFA) and conducted via secure, anonymous, electronic data capture using online REDCap 
database services [22] hosted at the University of Washington. Similarly, a link to the 
REDCap physician survey was emailed to all CFF Care Center Program Directors (81 adult 
and 88 pediatric programs) for secure, anonymous completion.
STOP Study
STOP (clinicaltrials.gov NCT02109822) was an observational pilot study conducted at 
eleven adult and pediatric CFF Therapeutic Development Network sites between 2014 and 
2015[18][19][21]. In brief, CF patients 12 years and older admitted to the hospital for a PEx 
were assessed for spirometry and patient-reported signs and symptoms throughout treatment 
and to Day 28. Human subjects approval was granted at all sites by their institutional review 
boards and written informed consent was obtained from all subjects.
Variables and Statistical Methods
Spirometry was conducted according to ATS standards [23] and forced expiratory volume in 
1 second (FEV1) is expressed as percent predicted [24]. Absolute changes in FEV1 % 
predicted from admission to Day 7–10, end of IV antibiotic treatment, and Day 28 were 
calculated. The CF Respiratory Symptom Diary (CFRSD) was scored according to the 
Chronic Respiratory Infection Severity Score (CRISS), where 100 is the most severe, and 0 
the least. Changes in CRISS and FEV 1 % predicted from admission to Day 7–10, end of IV, 
and Day 28 were summarized. We examined response defined as ‘early robust response’ 
(ERR) if absolute FEV1 and CRISS improvements from admission to Day 7–10 exceeded 
specific, candidate thresholds. For FEV1, we assessed response ranges from 5% to 10% 
predicted; for the CRISS we used the minimal clinically important response of 11 units [25]. 
Patients not meeting the thresholds at Day 7–10 were considered non-ERR (NERR). 
Candidate ERR thresholds were cross-tabulated with IV treatment duration and subsequent 
response at end of IV and Day 28. Means, standard deviations and 95% confidence intervals 
were used to calculate sample sizes and superiority/non-inferiority margins for a future 
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study. All analyses were performed using SAS (version 9.4, SAS Institute Inc., Cary, NC, 
2013), and R (version 3.2.1, The R Foundation for Statistical Computing, Vienna, Austria, 
2015).
RESULTS
Physician and Patient/caregiver (AFA) Surveys
102 of 169 CF physicians (60.4%) responded to the survey in July 2015: 44% were pediatric 
providers, 45% were adult providers, and 11% providing care to both, with even distribution 
across US regions. A majority (73%) of respondents had >10 years’ experience in CF care 
and most (78%) worked at centers with >100 patients. Just over one third (n=52) of the AFA 
completed the patient/caregiver survey in June 2015: 49% were persons with CF and 51% 
were parents, spouses, or partners of persons with CF; 37% of the surveyed CF population 
was <18 years of age. Nearly all (92%) reported IV antibiotic treatment of PEx for the 
person with CF at some time in the past. Detailed responses to questions regarding current 
PEx practices, interest in future studies, and clinical endpoints are in the online data 
supplement (Tables E1, E2). Key findings include: (1) both groups expressed high interest in 
studies of management of PEx (Table 1); (2) clinicians reported (80%) and patients/
caregivers assumed (85%) that antibiotics are selected based on recent culture and 
susceptibility testing; and (3) there were differences between clinicians and patients/families 
regarding most important treatment response measures: change in FEV1 (47% clinicians vs. 
17% patient/caregivers, respectively) and improvement in symptoms (32% clinicians vs. 
77% patient/caregivers). Both groups also offered additional comments (Tables E3, E4) with 
concerns expressed about too short a treatment duration, resulting in incomplete treatment, 
but also concern for receiving too long of a treatment.
Influence of Survey Results on STOP2 Study Design
STOP2 is a prospective comparison of different IV antibiotic treatment durations because 
both clinician and patient/caregiver surveys identified treatment duration as high-priority 
PEx management question (Table 1). Because the majority of those enrolled in the STOP 
pilot were adults [18] [19], and because pediatric patients are more likely to be treated with 
oral or inhaled antibiotics as a first line treatment [26], only STOP data from those 18 years 
and older were analyzed with the intent to restrict STOP2 to the adult population. The 
typical range of IV treatment durations across the US is 4–23.5 days [6], but we chose to 
compare the most common durations from the CFFPR: 10 (±1), 14 (±1), and 21 (±3) days 
[27]. To address survey respondents’ concerns of potential for overtreatment or under-
treatment, we conducted analyses to test a hypothesis that treatment duration inversely 
correlated with the magnitude of early treatment response, and used different FEV1 
thresholds ranging from 5–10% predicted change from admission to Day 7–10 to evaluate 
the proportion of patients who might be considered early robust responders (ERR) versus 
non-ERR (NERR) (Table 2). The Day 7–10 ERR threshold was made more stringent 
requiring that adults also experience a ≥11 point CRISS improvement from admission (Table 
2), the minimal clinically important symptom response in CF [25].
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Changes in mean FEV1 from admission to Day 7–10 were significantly higher in ERR 
(range: 14–18% predicted) than NERR (range: 2–4% predicted) (p<0.05), regardless of 
FEV1 threshold studied. Though attenuated, differences between ERR and NERR remained 
at Day 28 (Figure 1); ERR patients had a mean response at follow-up that was less than their 
mean response at Day 7–10, while NERR patients had an average FEV1 at follow-up that 
was greater than their Day 7–10 response (Figure 1).
To study how STOP adults’ experience compared to the proposed STOP2 treatment 
durations of 10 (±1), 14 (±1), and 21 (±3) days, we categorized STOP treatment durations as 
abbreviated (<12 days), intermediate (12–15 days), and extended (>15 days). Among 89 
STOP adults with complete Day 7–10 FEV1 and CRISS, and antibiotic treatment duration 
information, 18 (20.2%) received abbreviated, 43 (48.3%) received intermediate, and 28 
(31.5%) received extended durations. Distributions of antibiotic durations differed 
substantially by ERR/NERR categorization (Figure 2). Across ERR FEV 1 thresholds 
ranging from 5% to 10% predicted, the proportion of ERR patients receiving extended 
antibiotic treatments (which ranged from 7.4% to 12.2%) was substantially lower than the 
corresponding proportion of NERR patients (40.0% to 47.9%). Conversely, the proportion of 
NERR patients receiving abbreviated treatments (<15% at all thresholds) was lower than the 
proportion of ERR patients receiving abbreviated treatments (25–35% depending on FEV1 
threshold). These findings are consistent with a hypothesis that initial clinical response 
influences length of IV antibiotic treatment. Mean FEV 1 change from admission to Day 28 
for STOP adults stratified by antibiotic treatment duration and ERR/NERR threshold at Day 
7–10 are in Data Supplement Table E5.
To design STOP2 to mimic current treatment duration allocation, we compared the 
proportion of STOP adults receiving abbreviated and extended antibiotic treatments to the 
proportions of patients that would receive abbreviated and extended treatments were we to 
apply different thresholds to randomize ERR patients 1:1 to 10 (± 1) days (abbreviated) or 
14 (±1) days (intermediate) and NERR patients 1:1 to receive 14 (intermediate) or 21 (± 3) 
days (extended) of IV antibiotics (Figure E1). An FEV1 threshold of 7% predicted would 
assign 19.7% to receive abbreviated treatments –similar to the 20.2% in STOP who did 
receive <12 days treatment. Using an 8% predicted threshold would assign 32.0% of patients 
to receive extended treatments (31.5% in STOP received >15 days IV treatment). 
Conservatively, undertreating participants with a duration shorter than their providers would 
have chosen for them was considered higher risk than classifying a higher proportion of 
participants into NERR, therefore, 8% change in FEV1 and CRISS improvement of 11 or 
more at Day 7–10 was chosen to define ERR in STOP2. Figure 3 shows significantly higher 
FEV1 change in STOP ERR adults by this categorization (12.3% versus 4.0%, mean diff 
=8.3%, 95% CI=(4.8%, 11.8%), p <0.001). An 8% FEV 1 increase and 11 point CRISS 
reduction was not disproportionately experienced by patients with mild disease: 58% of 
ERR and 66% of NERR had low lung function (<50% predicted) at the start of treatment, 
and Data Supplement Table E6 shows clinical response in STOP by the chosen threshold 
and lung function at admission.
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STOP-2 Design and Hypotheses
Based on the clear divergence in treatment durations and outcome by early response, we 
suggest two separate hypotheses to test in STOP2: 1) abbreviated (10 ±1 day) IV treatment 
would not be inferior to 14 ±1 day treatment in ERR patients, and 2) extended (21 ±3 day) 
IV treatment would be superior to 14 ±1 day treatment in NERR patients. The proposed 
STOP2 study schema is shown in Figure 4.
In STOP2, adults with CF who are started on IV antibiotics for a PEx will be recruited to 
enroll in a randomized, controlled, open-label study designed to evaluate the efficacy and 
safety of differing durations of treatment. Treatment for the PEx can occur at home or in the 
hospital and physicians will be provided antibiotic selection and dosing guidelines to 
minimize variability of care. Participants will be evaluated at day 7–10 of treatment (Visit 2; 
Figure 4) and based on their categorization into ERR or NERR, patients will be randomized 
1:1 to 10 vs. 14 days (ERR) or 14 vs. 21 days (NERR) IV antibiotic treatment, respectively. 
The primary efficacy endpoint for both ERR and NERR is be absolute change in FEV1 % 
predicted from start of treatment to follow-up visit 14 days after scheduled completion of the 
assigned IV antibiotic treatment (Visit 3)[21]. Secondary and safety endpoints include 
change in CRISS symptom scores and weight, need for PEx re-treatment within 30 days of 
finishing IV treatment, time to next PEx (ascertained via the CFFPR), and adverse events. 
Airway clearance and continuation of chronic medications are encouraged [6]; 
corticosteroids and changes to antibiotics are permitted prior to randomization. 
Randomization will be stratified by location of treatment (exclusively home vs. any hospital 
days), FEV1 at treatment start (< vs ≥50 % predicted), history of IV antibiotics in the prior 
year(0–1 vs 2+), and systemic corticosteroid use. Blood and sputum will be collected at each 
visit for analysis of C-reactive protein, and sputum microbiome.
For ERR patients, we hypothesize that 10 days IV antibiotic treatment (ERR-10) is as safe as 
and not clinically inferior (in terms of lung function) to 14 days (ERR-14). With 155 
subjects per arm, the ERR study has 93% power (SD=9%) to detect a 3.5% non-inferiority 
margin, which preserves 72% of the treatment effect or 63% of the lower bound of treatment 
effect observed in STOP (ERR mean change 12.3% predicted at Day 28, 95% CI [9.3, 
15.3]).
The benefit of a prolonged course of IV antibiotics must outweigh potential risks of toxicity, 
treatment burden, and increased resource utilization. We hypothesize that 21 days 
(NERR-21) is clinically superior (in terms of lung function) and safe, compared to 14 days 
(NERR-14) IV antibiotic treatment. A superiority design among NERR requires 285 
subjects per arm to have 91% power (SD=9%) to detect a 2.5% greater increase in FEV1. 
Further details on sample size and design treatment effect for both ERR and NERR are in 
the online Data Supplemental as well as power for secondary endpoints.
We anticipate 1:2 distribution of subjects in the ERR and NERR groups based on our 
findings in STOP, and assuming 15% drop out both before randomization (Visit 2) and after, 
we expect to enroll approximately 1,200 adult CF patients and randomize approximately 
1,000 for 880 evaluable at Visit 3. Because STOP2 will enroll a slightly different patient 
population (including home IV, excluding patients who receive <7 days of IV antibiotics), an 
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early interim assessment of enrollment and feasibility will be performed, and safety will be 
overseen throughout the study by an independent data monitoring committee.
DISCUSSION
We have designed a large scale, randomized, controlled study of IV antibiotic duration for 
the treatment of PEx that balances concerns of inadequate treatment with the need to 
establish benefit from prolonged care. Optimizing the duration of antibiotic treatment has 
the potential for high impact because it is a known source of variability between and within 
centers [27]. We have incorporated the perceptions of both CF clinicians and patients/
families in design of the study; both groups deem the study of IV antibiotic duration 
important.
Shorter treatment duration may result in inadequate recovery or early relapse, while longer 
treatment might be associated with diminishing FEV1 improvement, extra cost and toxicity 
[27][28][29]. Identifying the optimal antibiotic duration in CF is important because it has 
implications on treatment decisions, antimicrobial resistance, complications from therapy, 
health care utilization, missed days of work and/or school, and cost effectiveness [30]. 
Previous studies in other respiratory infections (e.g. ventilator assisted pneumonia, 
community acquired pneumonia) have successfully reduced antibiotic burden in the hospital 
[31][32][33], and we believe the same can be shown for CF PEx. For the CF research 
community, a standardized duration will allow for the systematic evaluation of other adjunct 
therapies without the confounding effect of antibiotic duration. This will facilitate controlled 
trials to optimize other facets of PEx care: location (home versus hospital), administration of 
mucolytics or steroids, airway clearance techniques, antibiotic selection, route, or 
combination, etc., all of which are identified gaps in PEx treatment knowledge [6]. A widely 
accepted antibiotic treatment length has the potential to entice new investigational therapies 
in this area; the lack of standardized treatment protocols in CF PEx has discouraged drug 
development specifically targeted at treating acute respiratory events.
Survey response was not complete, which can introduce possible bias or lack of 
generalizability; however we identified concern expressed by CF clinicians, patients, and 
caregivers that early assignment to a specific treatment duration might be unacceptable for 
fear of premature cessation in the absence of improvement, as well as reluctance to commit 
to prolonged treatment when there is a rapid response. Our analyses of STOP data suggest 
that dividing a study population into ERR and NERR groups based upon clinical response 
observed between days 7 and 10 of treatment will likely mitigate those concerns. Patients 
identified as ERR were much less likely to be treated for extended periods exceeding 15 
days and were observed to have minimal additional benefit from intermediate 12–15 day 
treatments in comparison to abbreviated <12 day treatments. Thus, for ERR patients, the 
important clinical question is whether abbreviated treatment (10 days) provides no worse 
outcome than treatment for 14 days. In contrast, STOP NERR patients were much more 
likely to receive extended treatments and appeared to have additional FEV1 improvements 
during extended treatment, in comparison to intermediate treatment. For these patients, the 
clinical question is whether extended treatment (18–21 days) provides superior outcomes to 
treatment for 14 days, and will there be sufficient benefit to outweigh the cost and risks of 
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adverse events? While conceivable that patients could respond to the questionnaire at Day 7–
10 in a biased manner to influence their ERR/NERR determination, the 8% FEV1 recovery 
threshold serves as an impartial measure.
We proposed studying adult patients only because STOP had only 20% pediatric 
participation, thus providing insufficient data to adequately estimate treatment response in 
this population. Although this approach to treatment of PEx (i.e. early assessment of clinical 
response to determine treatment duration allocation) may be applicable to children, the 
safety and efficacy of fixed IV antibiotic durations must first be established in CF adults, 
before tailoring a study to the needs of the pediatric CF patient. It is also important to note 
that the primary endpoint is change in lung function from start of the PEx, rather than 
‘baseline’ in some period prior to the PEx. We chose this because STOP data showed that 
approximately 20% of patients start at their best FEV1 value at the time of IV antibiotic 
initiation [18] and there are no pre-PEx assessments of symptom scores [21]. Absolute 
change in FEV1 % predicted was chosen over relative change for efficiency, though the two 
endpoints have similar properties [21]. Timing of the final FEV1 measure was chosen to 
occur 14 days after the end of randomized treatment duration, so not to miss a decline in 
FEV1 that might occur after the end of IV due to inadequate treatment. However, many 
patients continue to improve after IV antibiotic treatment [34] including ~35% of STOP 
participants [21]. Thus, fixing the time interval from antibiotic cessation to measurement of 
the primary endpoint connotes a common experience for patients.
Research until now has reported varying predictors of PEx non-response or failure to 
therapy. Therefore, determining the set of appropriate IV antibiotic durations for 
randomization allocation in a CF population at the time of presentation with a PEx is not 
possible. There is no reliable presenting phenotype of a patient who would be a good 
candidate for a shorter IV antibiotic interval (10–14 days) versus an extended duration (14–
21 days). Half of the participants in STOP2 will receive 14 days of IV treatment (the most 
common duration currently observed in CF PEx)[27], making this a conservative protocol. 
We did not consider <10 days IV treatment based on a lack of willingness by physicians 
[19], the patient/caregiver survey results presented here, and reported poorer outcomes in 
patients treated for ≤9 days [27]. This study design carefully balances the risk of a too-short 
treatment, with the burden of an extended duration while mitigating the danger that the 
randomized arms would blur if patients and physicians went off study protocol to address 
PEx non-response as the participant neared the end of their allocated treatment duration. The 
‘delayed randomization’ also allows physician directed treatment decisions in the 7–10 day 
period before randomization to tailor patient care without jeopardizing the un-blinded study 
by potentially introducing confounding therapies.
CONCLUSIONS
We have designed and implemented the STOP2 study (NCT02781610) to evaluate patient 
lung function and symptom response after the first week of treatment to then randomize to 
an antibiotic duration that is appropriate for that patient based on their early response to 
treatment. The study design was based upon the interests of patients and clinicians and 
results of STOP data to effectively stratify the STOP-2 study into two patient populations 
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with differing PEx treatment needs and unique study hypotheses. We believe this study will 
provide the foundation for further improvements in PEx management
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Figure 1. Mean FEV1 change from admission through Day 7–10 and Follow-Up (Day 28) by 
ERR/NERR threshold
Panel A, Patients meeting the FEV1 improvement threshold and having a CRISS 
improvement of ≥11 points at Day 7–10 (ERR). Panel B, patients not meeting both the ERR 
FEV1 threshold and CRISS criteria at Day 7–10 (NERR). The X-axis shows the Day 7–10 
FEV1 change exceeded by ERR patients. Mean FEV1 changes at Day 7–10 are shown in 
white, mean FEV1 changes at Follow-Up are shown in gray. Sample sizes are shown in 
parentheses; bars are 95% confidence intervals for means. Day 7–10 total n=104 with both 
FEV1 and CRISS; Day 28 Follow-Up total n=89 with FEV1.
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Figure 2. Categorical antibiotic treatment durations for ERR and NERR patients across 
different ERR FEV1 thresholds
Panel A, STOP ERR adults; Panel B, STOP NERR adults. Open circles, patients treated less 
than 12 days. Gray circles, patients treated between 12 and 15 days. Black circles, patients 
treated >15 days. Total n=89 with FEV1 and CRISS at Day7–10 and treatment duration 
recorded.
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Figure 3. Mean absolute change in FEV1 % predicted in STOP adults
from start of IV antibiotic treatment to Day 7–10, end of IV treatment, and Day 28, by ERR 
(FEV1 ≥ 8% and CRISS improvement ≥11) and NERR (FEV1 < 8% or CRISS improvement 
<11). Vertical lines span from 25th to 75th percentiles; n at each time point shown on figure.
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Figure 4. STOP2 Study Schema
Patients enrolled in the study begin receiving IV antibiotics at Visit 1. Their change in FEV1 
and CRISS from Visit 1 is evaluated at Visit 2, between 7 and 10 days after Visit 1. Patients 
with an FEV1 improvement of ≥8% predicted and CRISS improvement of ≥11 points are 
allocated to the ERR (Early Robust Rersponse) study branch, where they will be randomized 
1:1 to receive either 10 (±1) or 14 (±) total days of antibiotic treatment. All other patients are 
allocated to the non-ERR (NERR) study branch, where they will be randomized 1:1 to 
receive either 14 (±1) or 21 (±3) total days of antibiotic treatment. Dark gray bars, IV 
antibiotic treatment; white bars, post-treatment follow-up; V, Study Visit; D, Study Day.
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Table 1
Ranking of clinical trial questions for improving treatment of pulmonary exacerbations
Rank Clinician Responses Higher Prioritya Patient/Family Responses Higher Prioritya
1 Antibiotic treatment duration 73% Site of treatment (home, hospital) 51%
2 1 vs. 2 antibiotics for Pab 48% When to start antibiotics 51%
3 Continuous infusion of β-lactam 38% Antibiotic route(s) 43%
4 Site of treatment (home, hospital) 35% Antibiotic treatment duration 40%
5 Use of corticosteroids 32% Use of corticosteroids 20%
a
Proportions of respondents identifying topic as 1st or 2nd highest priority to study
bPseudomonas aeruginosa airway infection
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